Aligos Therapeutics (ALGS) Net Margin (2021 - 2026)
Aligos Therapeutics' (ALGS) quarterly Net Margin came in at 814.13% in Q1 2026, down 1466880.0% YoY from N/an in Q1 2025, and up 93.08% on a QoQ basis from 11763.91% in Q4 2025.
Aligos Therapeutics (ALGS) Net Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 6 years of Net Margin data on file, last reported at 814.13% in Q1 2026.
- Quarterly Net Margin fell 1466880.0% year-over-year to 814.13% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2278.53% (down 11097241.0% YoY) and the FY2025 annual result came in at 1106.72%, up 3817801.0% from the prior year.
- Net Margin climbed to 814.13% in Q1 2026, from 11763.91% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 13854.66% in Q1 2025 to a low of 16396.43% in Q1 2023.
- A 5-year average of 1428.05% and a median of 814.13% in 2026 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin plunged 1501117 bps — and 2025, when it soared 1887815 bps.
- Tracing ALGS's Net Margin over 5 years: stood at 157.37% in 2022, then soared by 1657 bps to 2450.97% in 2023, then advanced by 25 bps to 3075.63% in 2024, then slumped by 482 bps to 11763.91% in 2025, then soared by 93 bps to 814.13% in 2026.
- The last three Net Margin figures came in at 814.13% (Q1 2026), 11763.91% (Q4 2025), and 1643.83% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 12.09% |
| 10 | Aligos Therapeutics | 66.76 Mn | 36.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -814.13% |
| Dec 31, 2025 | -11,763.91% |
| Jun 30, 2025 | -1,643.83% |
| Mar 31, 2025 | 13,854.66% |
| Dec 31, 2024 | 3,075.63% |
| Sep 30, 2024 | -1,540.72% |
| Jun 30, 2024 | 477.00% |
| Mar 31, 2024 | -5,023.49% |
| Dec 31, 2023 | 2,450.97% |
| Sep 30, 2023 | -1,662.76% |
| Jun 30, 2023 | -437.61% |
| Mar 31, 2023 | -16,396.43% |
| Dec 31, 2022 | -157.37% |
| Sep 30, 2022 | -453.51% |
| Mar 31, 2022 | -1,385.26% |
| Dec 31, 2021 | -10,276.29% |
| Sep 30, 2021 | -2,155.11% |
| Jun 30, 2021 | -1,929.97% |
| Mar 31, 2021 | -3,041.10% |